Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanomaGlobeNewsWire • 11/06/26
Immunocore reports third quarter financial results and provides a business updateGlobeNewsWire • 11/06/26
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meetingGlobeNewsWire • 10/29/26
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetesGlobeNewsWire • 10/15/26
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion StudyZacks Investment Research • 09/15/26
Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanomaGlobeNewsWire • 09/14/26
Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?Zacks Investment Research • 08/25/26
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More MomentumZacks Investment Research • 08/10/26
Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?Zacks Investment Research • 08/10/26
IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS MissZacks Investment Research • 08/10/26
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y RevenuesZacks Investment Research • 08/07/26
Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High?Zacks Investment Research • 08/07/26
Immunocore reports second quarter financial results and provides a business updateGlobeNewsWire • 08/06/26
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026GlobeNewsWire • 07/30/26
Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts AheadZacks Investment Research • 07/27/26
Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth?Zacks Investment Research • 07/27/26
Immunocore: KIMMTRAK Is Becoming A Cash Engine For A Much Larger TCR PlatformSeeking Alpha • 06/24/26
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanomaGlobeNewsWire • 05/31/26